Teva, Par Win Patent Appeal on Pronova Heart Drug in U.S.

Teva Pharmaceuticals USA Inc. and Par Pharmaceutical Cos. won an appeal in their bid to sell a generic version of BASF SE (BAS)’s heart medicine Lovaza in the U.S.

The U.S. Court of Appeals for the Federal Circuit in a ruling today said it reversed a lower court decision because one patent held by BASF’s Pronova unit had been made publicly accessible and another had expired.

The ruling sent shares of Amarin Corp., the maker of a competing medicine, down as much as 12 percent, the biggest drop since December 2012. Teva’s American depositary receipts, rose 1.1 percent to $38.94 at 12:14 p.m. New York time.

Lovaza is the first and only fish-oil derived prescription drug approved by the U.S. Food and Drug Administration, and Petach Tikva, Israel-based Teva and Par want to market generic versions, the court said in its ruling.

U.S. sales of Lovaza were more than $2.3 billion as of August 2010, the court said.

Pronova was acquired this year by Ludwigshafen, Germany-based BASF, and Par was bought last year by TPG Capital.

To contact the reporter on this story: Todd Shields in Washington at tshields3@bloomberg.net;

To contact the editor responsible for this story: Bernard Kohn at bkohn2@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.